Xenitra launches A$1.5M placement to fast-track higher-margin sales
Xenitra Limited (ASX:XEN) has received firm commitments to raise A$1.5 million before costs through a placement of 500,000,000 new fully paid ordinary shares at A$0.003 each. The offer price represents a 6.25% discount to the 15-trading-day volume-weighted average price (VWAP).
Investors will receive one free-attaching option for every two Placement Shares, exercisable at A$0.004 on or before 2 April 2028, subject to shareholder approval. Management has framed the raise as execution capital, directed at converting existing agreements and customer demand into rapidly growing, higher-margin sales.
When big ASX news breaks, our subscribers know first
Placement terms at a glance
The core mechanics of the transaction are summarised below.
| Term | Details |
|---|---|
| Gross proceeds | A$1.5 million before costs |
| Placement Shares | 500,000,000 new fully paid ordinary shares |
| Offer Price | A$0.003 per Placement Share |
| Placement Options | 250,000,000 free-attaching options (1-for-2), exercisable at A$0.004 on or before 2 April 2028, subject to shareholder approval |
| Offer Price discount | 6.25% to the 15-trading-day VWAP |
| Lead Manager | Novus Capital Limited (6% cash fee, 15,000,000 Broker Shares and 30,000,000 Broker Options, subject to shareholder approval) |
| Indicative allotment | Monday, 7 September 2026 |
Where the money goes: converting demand into sales
The proceeds are allocated across four areas, each tied directly to lifting sales capacity.
-
OTC and FSMP inventory and fulfilment: supplier payments, product procurement, inventory depth, logistics and purchase-order execution under the Kangsheng and Joy Charm relationships.
-
Ecommerce range expansion: new product listings and online activation through Fukang’s established Hong Kong and mainland China channels, including the JD.com storefront.
-
OPAL scale-up: onboarding additional brands and distribution partners, and supporting the sales, ecommerce and tokenisation infrastructure needed to increase tokenised product volumes.
-
Growth working capital and infrastructure: ongoing corporate costs through the coming financial year, together with the costs of the Placement.
Three commercial engines gaining momentum
Xenitra has moved from strategic reset to commercial execution across its Nutritionals and FMCG, OTC Medicines and OPAL businesses. Each channel offers a distinct pathway to higher-margin revenue.
OTC Medicines: a pharmaceutical channel now in market
Initial Fukang activity generated and fulfilled approximately A$450,000 in orders during July 2026 (preliminary and unaudited). This platform was established through the acquisition of Hong Kong Fukang Trading Co., which includes a Hong Kong pharmaceutical wholesale licence, an experienced local team, warehousing and logistics capability, and an active JD.com OTC storefront.
The three-year agreement with Kangsheng Pharmaceuticals Hong Kong Group carries a minimum A$12 million procurement commitment, providing commercial validation and a pathway to scale.
The Kangsheng OTC procurement agreement runs from July 2026 to July 2029, with Kangsheng operating an omnichannel network spanning e-commerce and retail pharmacies across China and reporting annual sales of approximately RMB900 million.
FSMP: extending into regulated medical foods
The Joy Charm framework agreement (announced 18 August 2026) targets A$5 million in Food for Special Medical Purposes (FSMP) procurement over three years, extending the company’s healthcare offering into regulated medical foods.
The target is not a guaranteed minimum. Sales will arise through individual purchase orders governing product, pricing, delivery and payment terms as the relationship is activated.
OPAL: early sales validation and expanding distribution
OPAL has generated more than A$1.5 million in tokenised product sales and onboarded over 500 distribution partners in less than one quarter following launch. According to the company, OPAL’s tokenised sales model carries a substantially higher margin profile than its historical nutritionals distribution business.
The OPAL distribution partner network grew from 100 to over 400 partners across Greater China within seven weeks of launch, a trajectory that contextualises the current milestone of more than 500 partners and over A$1.5 million in tokenised sales reported against less than one quarter of operation.
What is RWA tokenisation?
Real World Asset (RWA) tokenisation refers to representing physical products or inventory as digital tokens. In an FMCG context, this can streamline business-to-business (B2B) trading, retail distribution and ecommerce by using blockchain-enabled records to manage how goods move through sales channels.
Xenitra is described in the announcement as “one of the first Australian companies to commercially deploy Real World Asset (RWA) tokenisation integrated directly into mainstream FMCG sales channels in China.”
For investors, the relevance lies in the margin difference. A tokenised sales model reportedly commands a materially higher margin than traditional low-margin distribution, which is central to the company’s stated transition toward a diversified cross-border healthcare and digital-commerce platform.
A leaner platform already generating cash
The raise is underpinned by an operational turnaround. The latest reported quarter delivered A$800,000 in positive operating cash flow, alongside a 16% gross-margin improvement and approximately A$1 million in annualised operating savings.
These figures follow a strategic reset over the past year, described by management as a shift away from a “predominantly low-margin distribution model toward a diversified cross-border healthcare and digital-commerce platform” with materially higher-margin sales channels.
Chairman’s perspective
Dr Anthony Noble, Chairman of Xenitra
“This raising is deliberately focused on execution. It gives us working capital to support the ongoing operations of the business, including to purchase and move inventory, fulfil demand, widen our online product range and accelerate the onboarding of brands and distributors into OPAL. Our objective is straightforward: convert the agreements, channels and customer demand we have established into rapidly growing, higher-margin sales.”
The investment case and what comes next
The placement is positioned to fund the conversion of contracted procurement pipelines, including the Kangsheng minimum A$12 million commitment and the Joy Charm A$5 million target, along with OPAL’s early traction, into higher-margin revenue. Rather than survival capital, management has framed the funds as execution capital directed at revenue generation.
Key near-term markers include the indicative allotment date of 7 September 2026, with shareholder approval required for the Placement Options and the Lead Manager securities. Whether the contracted pipelines and demand translate into sustained sales growth remains dependent on execution across the three channels in the coming financial year.
Don’t Miss the Next Consumer Sector Move
Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Hit the “Free Alerts” button at StockWire X to get started today.